Journal of Gynecologic Oncology最新文献

{"title":"Comment of 'Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries'.","authors":"Sercan Ön","doi":"10.3802/jgo.2026.37.e133","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e133","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular subtyping: the missing piece in the FIGO 2023 IA3 downgrading of low-grade endometrioid carcinoma with adnexal involvement.","authors":"Aliza Arif, Sasha Zaki, Sangeen Khan","doi":"10.3802/jgo.2026.37.e142","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e142","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric non-gestational choriocarcinoma: a call for disease-specific treatment protocols.","authors":"Aliza Arif, Shahzaib Ali, Isheeka Lohana, Shanza Abbas","doi":"10.3802/jgo.2026.37.e146","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e146","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence and molecular subtyping in low-grade endometrioid carcinoma with adnexal involvement: a response to the commentary.","authors":"Jiyan Shang, Tianming Li, Yanmei Zhu","doi":"10.3802/jgo.2026.37.e145","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e145","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of first-line niraparib maintenance in Korean patients with advanced ovarian cancer: a multicenter retrospective cohort study.","authors":"Ok-Ju Kang, Myong Cheol Lim, Keun Ho Lee, Jae-Weon Kim, Byoung-Gie Kim, Yong Jae Lee, So-Jin Shin, Ki Hyung Kim, Dae Hoon Jeong, Jeong-Yeol Park","doi":"10.3802/jgo.2027.38.e34","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e34","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the real-world effectiveness of first-line niraparib maintenance therapy in Korean patients with advanced epithelial ovarian cancer (EOC) and assess outcomes across clinical and molecular subgroups.</p><p><strong>Methods: </strong>This multicenter retrospective study included patients with newly diagnosed International Federation of Gynecology and Obstetrics stage III-IV EOC who completed first-line platinum-based chemotherapy between December 2019 and October 2022 at nine tertiary institutions in South Korea. Patients were classified according to receipt of niraparib maintenance or no maintenance therapy. Propensity score matching was performed based on age, neoadjuvant chemotherapy, and <i>BRCA</i> mutation status. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 554 patients were included (niraparib, n=248; no maintenance, n=306). In the unmatched cohort, niraparib was associated with significantly longer PFS (p<0.001) and OS (p=0.001). After 1:1 matching, 189 pairs were analyzed. The 3-year PFS rate was higher in the niraparib group (43.1% vs 25.7%; p<0.001), as was the 3-year OS rate (86.3% vs 74.7%; p=0.005). PFS benefit was observed in both <i>BRCA</i>-mutated and <i>BRCA</i> wild-type subgroups. OS improvement was evident in the <i>BRCA</i> wild-type subgroup, with minimal post-progression crossover.</p><p><strong>Conclusion: </strong>First-line niraparib maintenance was associated with improved PFS regardless of <i>BRCA</i> status and with improved OS, particularly in <i>BRCA</i> wild-type patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT06086665.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes and clinical impact of HER3 and <i>ERBB3</i> expression in primary and recurrent ovarian cancer.","authors":"Kota Yokosu, Riu Yamashita, Satoshi Fujii, Hiroshi Tanabe, Toru Mukohara, Saori Sato, Maki Kobayashi, Keiko Oshima, Hiroko Kimura, Hiroyuki Takahashi, Motoaki Saito, Kyosuke Yamada, Hirokuni Takano, Aikou Okamoto, Kenichi Harano","doi":"10.3802/jgo.2027.38.e30","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e30","url":null,"abstract":"<p><strong>Objective: </strong>Human epidermal growth factor receptor (HER) 3, encoded by the <i>ERBB3</i> gene, transduces signals most effectively when dimerized with HER2. Although HER3 protein expression has been considered a poor prognostic factor in ovarian cancer, limited data exist on changes in HER3 protein expression and <i>ERBB3</i> messenger RNA (mRNA) expression during recurrence. This study evaluated HER3/ERBB3 expression before and after recurrence and its association with prognosis using paired samples. We also evaluated HER2/ERBB2 expression.</p><p><strong>Methods: </strong>We retrospectively analyzed 56 epithelial ovarian, fallopian tube, and primary peritoneal cancer patients who underwent primary cytoreduction and platinum-based chemotherapy at initial treatment and secondary cytoreduction at recurrence. HER2/HER3 protein expression was assessed by immunohistochemical staining. <i>ERBB2</i>/<i>ERBB3</i> mRNA expression was quantified using the nCounter® Analysis System.</p><p><strong>Results: </strong>The median age was 52 years. International Federation of Gynecology and Obstetrics stages I-IV included 16, 12, 22, and 6 patients, respectively. Histological subtypes included high-grade serous carcinoma (n=19), clear cell carcinoma (n=14), and other histological subtypes (n=23). The proportion of HER2-high and HER3-high tumors increased from 14.5% to 22.2% and from 62.5% to 72.2%, respectively, at recurrence, without statistical significance. Conversely, both <i>ERBB2</i> and <i>ERBB3</i> were significantly downregulated during recurrence. At initial treatment, HER3 did not correlate with prognosis, whereas <i>ERBB3</i> was independently associated with favorable recurrence-free and overall survival. At recurrence, neither HER3 nor <i>ERBB3</i> was prognostically significant.</p><p><strong>Conclusion: </strong><i>ERBB3</i> expression at initial treatment was associated with prognosis and significantly downregulated during recurrence. These findings suggest biological changes in HER3/<i>ERBB3</i> associated with recurrence.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of bevacizumab relative dose intensity with first-line treatment outcomes in advanced epithelial ovarian cancer.","authors":"Liming Zhang, Meilin Chen, Zhen Yang, Meiling Gong, Ruilian Yu","doi":"10.3802/jgo.2027.38.e28","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e28","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between bevacizumab relative dose intensity (RDI) and first-line treatment outcomes in advanced epithelial ovarian cancer.</p><p><strong>Methods: </strong>We retrospectively analyzed 72 patients treated with first-line bevacizumab plus paclitaxel-platinum chemotherapy between January 2019 and September 2024. Patients were categorized using X-tile-derived RDI cutoffs as low (≤0.61), intermediate (>0.61 to <0.93), or high (≥0.93). Objective response rate (ORR), progression-free survival (PFS), and adverse events were compared, and Cox proportional hazards regression was used to assess factors associated with PFS.</p><p><strong>Results: </strong>ORRs were 40.0%, 75.0%, and 80.0% in the low-, intermediate-, and high-RDI groups, respectively (p=0.011). Median PFS was 12.6, 21.2, and 23.5 months, respectively (log-rank p=0.037), with the greatest difference between the low- and high-RDI groups (p=0.018). In multivariable analysis, high versus low RDI was associated with a lower risk of progression (hazard ratio=0.463; 95% confidence interval=0.235-0.913; p=0.026). Overall adverse-event incidence did not differ significantly among groups; however, grade 3-4 neutropenia and thromboembolic events were significantly more frequent in the high- than low-RDI group.</p><p><strong>Conclusion: </strong>Lower bevacizumab RDI was associated with poorer response and shorter PFS. Given the retrospective single-center design, the optimal RDI threshold requires validation in larger prospective studies.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology.","authors":"Tadahiro Shoji, Tsukasa Baba, Yoichi Kobayashi, Hideki Tokunaga, Satoru Nagase, Kaoru Abiko, Muneaki Shimada, Masashi Takano, Wataru Yamagami, Hiroshi Tanabe, Akitoshi Nakashima, Hiroaki Kajiyama, Mikiko Asai-Sato, Munetaka Takekuma, Kazuhiro Takehara, Tsutomu Tabata, Shin-Ei Noda, Kenichi Harano, Yasuyuki Hirashima, Mayu Yunokawa, Tohru Morisada, Aikou Okamoto","doi":"10.3802/jgo.2026.37.e150","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e150","url":null,"abstract":"<p><p>To present the 2025 revision of the Japan Society of Gynecologic Oncology Clinical Practice Guidelines for the treatment of ovarian, fallopian tube, and primary peritoneal cancers, which incorporates recent advances in surgical strategies, molecular diagnostics, and maintenance therapies within the context of the Japanese healthcare system. Clinical questions (CQs) were formulated using the PICO framework. Systematic literature searches were conducted in PubMed, the Japan Medical Abstract Society, and the Cochrane Library (January 2019-December 2023), along with additional manual searches for emerging evidence. Three new systematic reviews addressing minimally invasive surgery, secondary cytoreductive surgery, and lymphadenectomy for malignant germ cell tumors were performed. Evidence levels and recommendation strengths were determined according to the Minds 2020 methodology adapted to the Japanese clinical and insurance environment. Recommendations were formulated using a modified GRADE approach. Final recommendations were established through multidisciplinary consensus voting, with a predefined agreement threshold of 75%. The sixth edition comprises 6 chapters and 49 CQs. Major updates include expanded guidance on homologous recombination deficiency testing and genomic profiling, refined indications for maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab, clarified recommendations for secondary cytoreductive surgery, updated management of PARP inhibitor-exposed recurrence, and strengthened sections on onco-fertility and palliative care. Transparency was enhanced by disclosing key discussion points and consensus rates for each recommendation. These guidelines define evidence-based standards tailored to Japanese clinical practice while maintaining international relevance. They aim to reduce inter-institutional disparities, optimize patient outcomes, and provide a transparent framework for future therapeutic integration.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of lymphadenectomy in surgical management of malignant ovarian germ cell tumors: a multi-center retrospective cohort study with inverse propensity of treatment weighting.","authors":"Xinyang Jin, Jiaxin Yang, Kezhen Zhang, Jing Zheng, Tianyu Zhang, Xinyue Zhang, Xuan Zong, Hui Zhang, Hua Li, Peng Peng, Dongyan Cao, Yang Xiang, Jie Yang","doi":"10.3802/jgo.2027.38.e26","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e26","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between lymphadenectomy (LND) and survival outcomes in malignant ovarian germ cell tumors.</p><p><strong>Methods: </strong>In this multi-center, retrospective cohort study, patients surgically treated for malignant ovarian germ cell tumors at three tertiary hospitals in China between 2016 and 2023 were included. Progression-free survival (PFS), surgical performance and perioperative complications were analyzed. An inverse propensity of treatment weighting model was performed to minimize selection bias.</p><p><strong>Results: </strong>A total of 213 patients were eligible for analysis, of whom 57 (26.8%) underwent LND and 156 (73.2%) did not. The overall rate of lymph-node metastasis was 17.5% (immature teratoma 0%, yolk sac tumor 9.5%, dysgerminoma 27.8%). LND was associated with increased operative time (p<0.001), hospital stay (p=0.019) and estimated blood loss (p=0.007). No significant difference was identified in the 5-year PFS between the 2 groups before and after inverse propensity of treatment weighting adjustment. Multivariate analysis showed the delayed post-operative chemotherapy and unfavorable pathological types (yolk sac tumor and mixed malignant germ cell tumors) were independent predictors of survival (hazard ratio [HR]=2.86, 95% confidence interval [CI]=1.27-6.44, p=0.011; HR=2.88, 95% CI=1.03-8.08, p=0.044; and HR=3.90, 95% CI=1.37-11.08, p=0.011, respectively).</p><p><strong>Conclusion: </strong>Our study indicated that LND was not associated with a survival benefit but increased surgical morbidity in patients with malignant ovarian germ cell tumors, underscoring the critical importance of timely chemotherapy. However, it may still be considered in select cases, such as for imaging-suspected dysgerminoma.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment.","authors":"Shiho Kuji, Mohd Faizal Ahmad, Syamel Muhammad, Sarita Kumari, Romelyn Imperio-Onglao, Shohei Iyoshi, Masato Yoshihara, Siew Fei Ngu, Allen Gideon Tan, Sanghoon Lee, Pinyada Panyavaranant, Jennifer Ko, Very Great Eka Putra, Min-Hyun Baek, Rudrika Chandra, Yu Xue, Doris R Benavides, Tingyan Shi, Navamol Lekskul, Angela Cho, Biswajit Dash, Ling Lim, Christine Shan-Chi Chiu, Reeta Mahey, Se Ik Kim, Virgilio M Novero, Geon Woo Lee, Emiri Miyamoto, Motohiro Chosokabe, Motoki Takenaka, Kensuke Sakai, Kosuke Shigematsu, Jae-Weon Kim, Hiroaki Kajiyama, Nao Suzuki","doi":"10.3802/jgo.2027.38.e21","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e21","url":null,"abstract":"<p><strong>Objective: </strong>To examine current practices of fertility preservation (FP) and infertility treatment after fertility-sparing surgery for borderline ovarian tumors (BOTs) across Asian regions.</p><p><strong>Methods: </strong>A cross-national survey was conducted among gynecologic oncology experts in 10 Asian regions (Chinese Mainland, Hong Kong, India, Indonesia, Japan, Malaysia, South Korea, Taiwan, Thailand, and the Philippines) using a 7 survey questions assessing ovarian function monitoring, FP timing and methods, and management after childbirth or recurrence.</p><p><strong>Results: </strong>Ovarian function was routinely monitored in 7 of the 10 regions (70%), although the methods and duration of follow-up varied. Oocyte pickup was performed intraoperatively in 5 of the 10 regions (50%) and postoperatively in 7 of the 10 regions (70%). Three of the 10 regions (30%) routinely performed completion surgery after childbirth, which appeared to be less common in high-income regions. FP in recurrent BOT was considered feasible in 8 regions (80%).</p><p><strong>Conclusion: </strong>Inter regions differences were observed in the adoption of advanced assisted reproductive technologies for BOT and in the prioritization of FP. Because the oncologic safety of these approaches remains supported by limited evidence, further studies are required before their widespread implementation in clinical practice. In addition, consensus based on robust evidence, including oncologic outcomes, is needed regarding the management of recurrence and post-childbirth treatment strategies.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}